Delayed
Nasdaq
04:30:00 2024-05-30 pm EDT
|
5-day change
|
1st Jan Change
|
6.51
USD
|
+2.36%
|
|
+1.45%
|
-21.09%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
17.39
|
11.14
|
23.29
|
10.11
|
11.46
|
6.215
|
Enterprise Value (EV)
1 |
12.41
|
10.36
|
18.68
|
4.374
|
8.706
|
0.0198
|
P/E ratio
|
-1.69
x
|
-0.27
x
|
-0.68
x
|
-1.13
x
|
-1.03
x
|
-1.11
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
2.63
x
|
3.08
x
|
4.81
x
|
6.63
x
|
20.6
x
|
33.8
x
|
EV / Revenue
|
1.87
x
|
2.87
x
|
3.86
x
|
2.87
x
|
15.6
x
|
0.11
x
|
EV / EBITDA
|
-1.57
x
|
-0.62
x
|
-2.65
x
|
-0.48
x
|
-0.87
x
|
-0
x
|
EV / FCF
|
-2.08
x
|
-1.12
x
|
-5.01
x
|
-0.96
x
|
-1.84
x
|
-0
x
|
FCF Yield
|
-48%
|
-89.3%
|
-20%
|
-105%
|
-54.3%
|
-28,458%
|
Price to Book
|
2.55
x
|
7.77
x
|
6.65
x
|
1.97
x
|
8.63
x
|
0.97
x
|
Nbr of stocks (in thousands)
|
21.7
|
95.6
|
354
|
496
|
731
|
753
|
Reference price
2 |
802.8
|
116.5
|
65.80
|
20.40
|
15.66
|
8.250
|
Announcement Date
|
4/1/19
|
3/30/20
|
3/31/21
|
3/25/22
|
3/31/23
|
4/1/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
6.618
|
3.611
|
4.838
|
1.526
|
0.557
|
0.184
|
EBITDA
1 |
-7.884
|
-16.6
|
-7.059
|
-9.133
|
-10.04
|
-7.165
|
EBIT
1 |
-8.264
|
-16.84
|
-7.351
|
-9.354
|
-10.24
|
-7.277
|
Operating Margin
|
-124.87%
|
-466.46%
|
-151.94%
|
-612.98%
|
-1,837.52%
|
-3,954.89%
|
Earnings before Tax (EBT)
1 |
-9.023
|
-16.46
|
-7.407
|
-8.776
|
-10.21
|
-5.569
|
Net income
1 |
-9.023
|
-16.46
|
-18.24
|
-8.776
|
-10.21
|
-5.569
|
Net margin
|
-136.34%
|
-455.77%
|
-377.06%
|
-575.1%
|
-1,832.32%
|
-3,026.63%
|
EPS
2 |
-473.7
|
-432.0
|
-96.70
|
-18.04
|
-15.19
|
-7.406
|
Free Cash Flow
1 |
-5.955
|
-9.248
|
-3.728
|
-4.573
|
-4.727
|
-5.646
|
FCF margin
|
-89.99%
|
-256.1%
|
-77.06%
|
-299.69%
|
-848.63%
|
-3,068.55%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
4/1/19
|
3/30/20
|
3/31/21
|
3/25/22
|
3/31/23
|
4/1/24
|
Fiscal Period: December |
2022 Q1
|
2022 Q2
|
2022 Q3
|
---|
Net sales
1 |
-
|
0.15
|
0.095
|
EBITDA
|
-
|
-
|
-
|
EBIT
1 |
-
|
-2.442
|
-2.643
|
Operating Margin
|
-
|
-1,628%
|
-2,782.11%
|
Earnings before Tax (EBT)
1 |
-
|
-2.462
|
-2.638
|
Net income
1 |
-2.54
|
-2.462
|
-2.638
|
Net margin
|
-
|
-1,641.33%
|
-2,776.84%
|
EPS
2 |
-4.800
|
-3.600
|
-3.600
|
Dividend per Share
|
-
|
-
|
-
|
Announcement Date
|
5/16/22
|
8/11/22
|
11/14/22
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
4.98
|
0.78
|
4.6
|
5.74
|
2.75
|
6.2
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-5.96
|
-9.25
|
-3.73
|
-4.57
|
-4.73
|
-5.65
|
ROE (net income / shareholders' equity)
|
-235%
|
-398%
|
-298%
|
-202%
|
-314%
|
-139%
|
ROA (Net income/ Total Assets)
|
-44.9%
|
-89.2%
|
-52.2%
|
-72.7%
|
-106%
|
-74.9%
|
Assets
1 |
20.09
|
18.46
|
34.96
|
12.07
|
9.614
|
7.435
|
Book Value Per Share
2 |
315.0
|
15.00
|
9.890
|
10.40
|
1.820
|
8.500
|
Cash Flow per Share
2 |
429.0
|
54.60
|
15.20
|
12.20
|
3.910
|
8.650
|
Capex
1 |
0.42
|
0.26
|
0.54
|
0.02
|
-
|
0
|
Capex / Sales
|
6.29%
|
7.09%
|
11.16%
|
1.51%
|
-
|
1.09%
|
Announcement Date
|
4/1/19
|
3/30/20
|
3/31/21
|
3/25/22
|
3/31/23
|
4/1/24
|
|
1st Jan change
|
Capi.
|
---|
| -21.09% | 5.95M | | +42.15% | 739B | | +32.90% | 598B | | -5.13% | 353B | | +17.94% | 318B | | +5.08% | 285B | | +16.53% | 240B | | +9.46% | 210B | | -5.36% | 206B | | +7.78% | 164B |
Other Pharmaceuticals
|